Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Rationale: Infertility due is a major concern for girls with Turner syndrome (TS) and their parents. Physicians are often asked about possible options to preserve their fertility. However, despite some experimental case reports, clear evidence for fertility preservation in these girls is lacking and many questions remain. Without evidence on the effectiveness of fertility preservation it cannot routinely be offered to girls with TS.
Objective: To investigate the occurrence of live birth in women with TS after ovarian tissue cryopreservation in childhood followed by auto transplantation in adulthood.
Study design: A national multicentre exploratory intervention study
Study population: Girls diagnosed with Turner Syndrome, aged 2-18 years.
Intervention: Ovarian tissue cryopreservation in childhood followed by auto transplantation in adulthood. In order to obtain the ovarian tissue for cryopreservation, all girls must undergo a laparoscopy under general anaesthesia which will be performed in academic/university clinics with paediatric surgery. During the laparoscopic intervention, a unilateral oophorectomy will be performed, thereby leaving the other ovary intact for hormone production, ovulation, spontaneous pregnancies and as an auto transplantation site for cryopreserved-thawed ovarian cortical tissue later on. Furthermore, a small sample of the ovarian cortex will be used to assess the oocyte quality and genetics (e.g. the presence of germ line mosaicism). Oocytes will be karyotyped by using Fluorescence in situ hybridization (FISH). Karyotypic and hormonal data will be collected once at the yearly clinical visit at the paediatric-endocrinologist. Therefore, a buccal swab and one extra blood sample will be taken and evaluated during the routine laboratory evaluation.
In the future, auto transplantation of frozen-thawed ovarian cortex strips will be performed.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness:
The primary objective remains to preserve the fertility of the respective (minor) patient, facing a very high risk of premature ovarian insufficiency (POI) of 95-98%. Disadvantages of participating in this study are the potential risk of complications related to the laparoscopic unilateral oophorectomy and/or the unknown effect on future fertility of these girls. Moreover, the procedure might raise false hope in patients (and/or parents) about the chance of getting pregnant after auto transplantation of cryopreserved-thawed ovarian tissue in the future. However, we attempt to overcome this by extensive and objective information provision by both written materials and face to face counselling.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Single cohort | Other |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Ovarian tissue cryopreservation | Procedure | Laparoscopic unilateral oophorectomy followed by cryopreservation of ovarian cortex tissue |
|
| Measure | Description | Time Frame |
|---|---|---|
| Live birth ratio (LBR) (main outcome) | • Live birth after auto transplantation of cryopreserved-thawed ovarian cortical tissue (i.e. live birth rate or LBR) | Up to 3 years after auto transplantation of cryopreserved-thawed ovarian cortical tissue, and up to 45 years after ovarian tissue cryopreservation. |
| Number of primordial follicles (proximate) | The number of primordial follicles found in the ovarian tissue | Within 1 month after ovarian tissue cryopreservation |
| Measure | Description | Time Frame |
|---|---|---|
| Patient's age versus LBR | The association between patient's age at cryopreservation and LBR | Up to 3 years after auto transplantation of cryopreserved-thawed ovarian cortical tissue, and up to 45 years after ovarian tissue cryopreservation. |
| Patient's genotype versus LBR |
| Measure | Description | Time Frame |
|---|---|---|
| Study participation rate | The willingness of girls with TS to perform a unilateral oophorectomy for fertility preservation (i.e. the study participation rate) | Up to 3 years after inclusion |
| Eligible participants |
Inclusion criteria
In order to be eligible to participate in this study, a subject must meet all of the following criteria:
Exclusion Criteria:
A potential subject who meets any of the following criteria will be excluded from participation in this study:
Contra-indications for laparoscopic unilateral oophorectomy under general anaesthesia (e.g. severe cardiovascular comorbidity and/or BMI >40 kg/m2)*,
Contra-indications for cryopreservation (i.e. active HIV, hepatitis-B or hepatitis-C infection)
Patients 45X monosomy of mosaicism
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Kathrin Fleischer, MD, PhD | Head Department of Reproductive Medicine, Gynaecologist/Subspecialist Reproductive Medicine | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Radboud university medical center. Department Obstetrics & Gynaecology. | Nijmegen | Gelderland | 6500HB | Netherlands |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 28705803 | Background | Gravholt CH, Andersen NH, Conway GS, Dekkers OM, Geffner ME, Klein KO, Lin AE, Mauras N, Quigley CA, Rubin K, Sandberg DE, Sas TCJ, Silberbach M, Soderstrom-Anttila V, Stochholm K, van Alfen-van derVelden JA, Woelfle J, Backeljauw PF; International Turner Syndrome Consensus Group. Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting. Eur J Endocrinol. 2017 Sep;177(3):G1-G70. doi: 10.1530/EJE-17-0430. | |
| 39433199 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Jun 24, 2020 | Oct 6, 2020 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D014424 | Turner Syndrome |
| D016649 | Primary Ovarian Insufficiency |
| ID | Term |
|---|---|
| D006059 | Gonadal Dysgenesis |
| D012734 | Disorders of Sex Development |
| D014564 | Urogenital Abnormalities |
| D052776 | Female Urogenital Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The association between patient's genotype and LBR |
| Up to 3 years after auto transplantation of cryopreserved-thawed ovarian cortical tissue, and up to 45 years after ovarian tissue cryopreservation. |
| Patient's Anti-Müllerian hormone (AMH) level versus LBR | The association between patient's AMH level at cryopreservation and LBR | Up to 3 years after auto transplantation of cryopreserved-thawed ovarian cortical tissue, and up to 45 years after ovarian tissue cryopreservation. |
| Patient's Follicle-stimulating hormone (FSH) level versus LBR | The association between patient's FSH level at cryopreservation and LBR | Up to 3 years after auto transplantation of cryopreserved-thawed ovarian cortical tissue, and up to 45 years after ovarian tissue cryopreservation. |
The number of eligible participants
| Up to 3 years after inclusion |
| Age | The age of the participant | Up to 3 years after inclusion |
| Buccal cells versus peripheral lymphocytes | The incidence of somatic mosaicism (i.e. buccal cells versus peripheral lymphocytes) | Up to 3 years after inclusion |
| Ovarian cells versus peripheral lymphocytes | The incidence of germ cell mosaicism (i.e. ovarian cells versus peripheral lymphocytes and buccal cells) | Up to 3 years after inclusion |
| Serum hormone levels | Serum hormone levels (i.e. FSH, Luteinizing hormone (LH), AMH, E2, inhibin B) | Up to 3 years after inclusion |
| Complication rate | The number of complications related to the laparoscopic procedure | Up to 1 year after the laparoscopic procedure |
| Influence of laparoscopic oophorectomy on puberty and/or menarche | The incidence of puberty and/or menarche after laparoscopic oophorectomy | Up to 10 years after the laparoscopic procedure |
| Incidence of spontaneous pregnancies | The incidence of spontaneous pregnancies after laparoscopic oophorectomy | Up to 45 years after the laparoscopic procedure |
| Restoration of ovarian function after auto transplantation of ovarian tissue | The incidence of menstruation cycle recovery after auto transplantation of cryopreserved-thawed ovarian tissue in the future | Up to 2 years after auto transplantation of cryopreserved-thawed ovarian cortical tissue |
| Pregnancies after auto transplantation of ovarian tissue | The incidence of pregnancies after auto transplantation of cryopreserved-thawed ovarian tissue in the future | Up to 2 years after auto transplantation of cryopreserved-thawed ovarian cortical tissue |
| Ongoing pregnancies after auto transplantation of ovarian tissue | The incidence of ongoing pregnancies after auto transplantation of cryopreserved-thawed ovarian tissue in the future | Up to 2 years and 3 months after auto transplantation of cryopreserved-thawed ovarian cortical tissue |
| Miscarriages after auto transplantation of ovarian tissue | The number of miscarriages after auto transplantation of cryopreserved-thawed ovarian tissue in the future | Up to 3 years after auto transplantation of cryopreserved-thawed ovarian cortical tissue |
| Time to pregnancy after auto transplantation of ovarian tissue | Time to pregnancy after auto transplantation of cryopreserved-thawed ovarian tissue in the future | Up to 2 years after auto transplantation of cryopreserved-thawed ovarian cortical tissue |
| Time to live birth after auto transplantation of ovarian tissue | Time to live birth after auto transplantation of cryopreserved-thawed ovarian tissue in the future | Up to 3 years after auto transplantation of cryopreserved-thawed ovarian cortical tissue |
| Derived |
| van der Coelen S, Nadesapillai S, Peek R, Braat D, Bocca G, Finken M, Hannema S, de Kort S, Sas T, Straetemans S, van Tellingen V, Stuart AV, Fleischer K, van der Velden J. Puberty progression in girls with Turner syndrome after ovarian tissue cryopreservation. Fertil Steril. 2025 Apr;123(4):583-592. doi: 10.1016/j.fertnstert.2024.10.025. Epub 2024 Oct 19. |
| 37549836 | Derived | Nadesapillai S, van der Velden J, van der Coelen S, Schleedoorn M, Sedney A, Spath M, Schurink M, Oerlemans A, IntHout J, Beerendonk I, Braat D, Peek R, Fleischer K. TurnerFertility trial: fertility preservation in young girls with Turner syndrome by freezing ovarian cortex tissue-a prospective intervention study. Fertil Steril. 2023 Nov;120(5):1048-1060. doi: 10.1016/j.fertnstert.2023.08.004. Epub 2023 Aug 5. |
| 33342535 | Derived | Nadesapillai S, van der Velden J, Smeets D, van de Zande G, Braat D, Fleischer K, Peek R. Why are some patients with 45,X Turner syndrome fertile? A young girl with classical 45,X Turner syndrome and a cryptic mosaicism in the ovary. Fertil Steril. 2021 May;115(5):1280-1287. doi: 10.1016/j.fertnstert.2020.11.006. Epub 2020 Dec 17. |
| 31831533 | Derived | Schleedoorn M, van der Velden J, Braat D, Beerendonk I, van Golde R, Peek R, Fleischer K. TurnerFertility trial: PROTOCOL for an observational cohort study to describe the efficacy of ovarian tissue cryopreservation for fertility preservation in females with Turner syndrome. BMJ Open. 2019 Dec 11;9(12):e030855. doi: 10.1136/bmjopen-2019-030855. |
| 31398245 | Derived | Peek R, Schleedoorn M, Smeets D, van de Zande G, Groenman F, Braat D, van der Velden J, Fleischer K. Ovarian follicles of young patients with Turner's syndrome contain normal oocytes but monosomic 45,X granulosa cells. Hum Reprod. 2019 Sep 29;34(9):1686-1696. doi: 10.1093/humrep/dez135. |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D058533 | Sex Chromosome Disorders of Sex Development |
| D052801 | Male Urogenital Diseases |
| D006330 | Heart Defects, Congenital |
| D018376 | Cardiovascular Abnormalities |
| D002318 | Cardiovascular Diseases |
| D006331 | Heart Diseases |
| D000013 | Congenital Abnormalities |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D025064 | Sex Chromosome Disorders |
| D025063 | Chromosome Disorders |
| D030342 | Genetic Diseases, Inborn |
| D006058 | Gonadal Disorders |
| D004700 | Endocrine System Diseases |
| D010049 | Ovarian Diseases |
| D000291 | Adnexal Diseases |
| D005831 | Genital Diseases, Female |
| D000091662 | Genital Diseases |